Download a 29-page Preview Guide (pdf) to the 2013 National Rx Drug Abuse Summit.
|Access to Treatment
Tuesday, April 2, 2013, 12:30 pm – 1:45 pm
|Moderator||Dr. Kelly Clark, MD, MBA, FASAM, DFAPA
Chief Medical Officer, Behavioral Health Group
|Presenters||Dr. Stuart Gitlow, MD, MPH, MBA
President, American Society of Addiction Medicine
Dr. Robert Newman, MD, MPH
Director, Baron Edmond de Rothschild Chemical Dependency Institute of Beth Israel Medical Center
|Session Description||The Centers for Disease Control and Prevention (CDC) finds that 15,000 people die each year from prescription drug abuse, many of whom could still be living had there been greater access to treatment. In response to the epidemic of prescription drug addiction, there has been significant effort to decrease the prescribing of opioids for pain and to raise the awareness of the dangers of these medications, but treatment options must still be prescribed for millions of patients. There are numerous barriers to effective and long-term treatment options.
This session will describe the types of treatment available for opioid addiction and an overview of the evidence base that supports the clinical and cost effectiveness of various forms of treatment. In addition, barriers to obtaining needed treatment will be discussed, focusing on regulatory and insurance limitations which treat addiction differently than other diseases. We’ll also discuss the special difficulties faced in obtaining treatment by our active duty military personnel and veterans.
|Learning Objectives||1. List the types of treatment available for opioid addiction, and some of the evidence to support treatment.
2. Explain how regulatory and insurance policies form barriers to treatment.
3. Define the special problems our active duty military and veterans have in accessing treatment for opioid addiction.
|Treatment Options for Juveniles
Tuesday, April 2, 2013, 2:00 pm – 3:15 pm
Treatment Director, Operation UNITE
|Presenters||Dr. Marc Fishman, MD
Medical Director, Maryland Treatment Centers, and Assistant Professor, Johns Hopkins University Department of Psychiatry
Michelle Lipinski, MEd
Principal, Northshore Recovery High School, and Principal/Founder, icanhelp Program
|Session Description||SAMHSA states that 70 percent of people 12 years of age and older who abuse prescription drugs say they get them from a friend or relative. The diversion of prescription medication to juveniles poses a tremendous problem to our communities, and the need to educate juveniles of the dangers of prescription drug abuse should be a top priority.
This session will feature two strategies for the treatment of juveniles. One focuses on the cycle of addiction by understanding deprivation and dependency as precursors to experiencing a substance abuse problem. Another method is a program for early engagement by establishing “safe” places for adolescents to develop a trusting rapport with adults in the community.
|Learning Objectives||1. Define dependency and deprivation.
2. Identify states of the World of Abnormal Rearing (WAR) cycle.
3. Explain clinical interventions to break the cycle of addiction.
4. Plan how to collaborate with law enforcement and the medical community to bring support to juveniles.
|A Comprehensive Response to the Opioid Crisis
Tuesday, April 2, 2013, 3:30 pm – 4:45 pm
|Moderator||Regina M. LaBelle
Chief of Staff, White House Office of National Drug Control Policy
|Presenters||Scott Hesseltine, MA, LADC
Chemical Dependency Program Supervisor, Hazelden Foundation
Lodge Program Director, Hazelden Foundation
Dr. Marvin D. Seppala
Chief Medical Officer, Hazelden Foundation
|Session Description||According to SAMHSA’s National Survey on Drug Use and Health, 23.5 million persons aged 12 or older needed treatment for a substance abuse in 2009. Of these, only 2.6 million — 11.2 percent of those who needed treatment — received it at a specialty facility. According to the National Center on Addiction and Substance Abuse at Columbia University (CASA), 58 percent of federal and state spending for substance abuse and addiction is in health care costs.
In this session attendees will hear how Hazelden has examined their opioid dependence treatment services to enhance the treatment of opioid-dependent patients. Some of their enhancements include reinforcing their knowledge of treatment of opioid dependence, altering group therapy, and instituting protocols for the use of evidence-based medication-assisted treatment.
|Learning Objectives||1. Identify warning signs of misuse and abuse and how claim managers can take action.
2. Describe the treatment experience.
3. Outline how to employ a 12-step, abstinence-based treatment program.
|SAMHSA’s Tools for Treatment
Wednesday, April 3, 2013, 1:30 pm – 2:45 pm
|Moderator||CDR Jinhee Lee
Public Health Advisor, Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, SAMHSA
|Presenters||Dr. Melinda Campopiano, MD
Medial Officer, Substance Abuse and Mental Health Services Administration (SAMHSA)
Suzanne Fields, MSW, LICSW
Senior Advisor to the SAMHSA Administration on Health Care Financing, SAMHSA
|Session Description||The Office of National Drug Control Policy (ONDCP) found that the total spent on drug abuse treatment in 2011 was $8.9 billion. According to the Affordable Care Act of 2012 (ACA), comprehensive health insurance reforms were established that will make health insurance available to many more people, lower health care costs, guarantee more health care choices, and enhance the quality of health care for all Americans. The ACA includes substance use disorders as one of the 10 elements of essential health benefits.
In this session, attendees will learn tools for treatment that have been established by SAMHSA and how the ACA will make it possible for millions of Americans, many in or seeking recovery, to be included in the healthcare system for the first time. A discussion on medicated-assisted treatment will follow, including a treatment toolkit which participants can implement in their community.
|Learning Objectives||1. Identify SAMHSA’s tools for treatment.
2. Identify the methods for medicated-assisted treatment.
3. Analyze the ACA and its effect on access to treatment
|Neonatal Abstinence Syndrome: Treating Pregnant Women
Wednesday, April 3, 2013, 3:00 pm – 4:15 pm
Treatment Director, Operation UNITE
|Presenters||Gail A. Bagwell RN, MSN, CNS
Clinical Nurse Specialist for Perinatal Outreach, Nationwide Children’s Hospital
Clinical Pharmacy Specialist – NICU, Nationwide Children’s Hospital
Dr. Richard E. McClead Jr.
Professor and Vice Chairman, Department of Pediatrics, The Ohio State University
Dr. Mona Prasad, DO, MPH
Medical Director of STEPP, Ohio State University
|Session Description||Opioid use in pregnancy is not uncommon, and the use of illicit opioids during pregnancy is associated with an increased risk of adverse outcomes. According to The Journal of the American Medical Association, every hour a baby is born in the United States with symptoms of withdrawal from opiates.
In this session, attendees will learn the latest protocol standards for treating pregnant women when they are opioid dependent. Stigma affects all opioid-dependent patients to some degree, but prejudice toward those who become pregnant is especially high. Staff must provide patient care in a nonjudgmental way, conveying an understanding of the patient’s fears and cultural or ethnic beliefs. We’ll also discuss how pregnant patients in medicated-assisted treatment can have complex medical issues, as well as co-occurring mental health issues that require careful management.
| Learning Objectives
||1. Explain how to screen pregnant women for opioid dependency.
2. Plan how to collaborate between the patient’s OBGYN and an addiction medicine specialist.
3. Define the standard of care for infants born to women who used opioids during pregnancy for NAS and other effects of opioid use.